<DOC>
	<DOCNO>NCT02726022</DOCNO>
	<brief_summary>Participants Chronic Hepatitis C ( CHC ) normal ALT , treatment peginterferon alfa-2a ribavirin least 4 week , enrol non-interventional , open-label study . The primary aim evaluate quality life accord 36-Item Short-Form Health Survey ( SF-36 ) questionnaire , modify Greek population .</brief_summary>
	<brief_title>A Quality Life Study Peginterferon-Alfa-2a Plus Ribavirin Participants With Chronic Hepatitis C Persistently Normal Alanine Transaminase ( ALT ) Levels</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Serological confirmation chronic infection antihepatitis C virus ( HCV ) assay HCV ribonucleic acid ( RNA ) positive CHC normal transaminase Compensated liver disease Nonpregnant willing use two contraceptive method ( fertile ) At least 4 week prior treatment peginterferon alfa2a ribavirin Pregnant lactate woman Coinfection hepatitis A B , human immunodeficiency virus ( HIV ) History seizures depression History autoimmune disease , severe heart lung disease , renal failure reduce creatinine clearance Uncontrolled thyroid disease Severe retinopathy Leukopenia thrombocytopenia Bleeding esophageal varix evidence hepatic decompensation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>